Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)

v3.7.0.1
Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2017
Notes Tables  
Schedule of Franchisor Disclosure [Table Text Block]
    Three Months Ended
    March 31,
Franchised clinics:   2017   2016
Clinics open at beginning of period    
309
      
265
  
Opened or purchased during the period    
18
      
14
  
Acquired during the period    
-
      
-
  
Closed during the period    
(1
 )    
(2
 )
Clinics in operation at the end of the period    
326
      
277
  
    March 31,
Company-owned or managed clinics:   2017   2016
Clinics open at beginning of period    
61
      
47
  
Opened during the period    
-
      
7
  
Acquired during the period    
-
      
-
  
Closed or sold during the period    
(14
 )    
-
  
Clinics in operation at the end of the period    
47
      
54
  
                 
Total clinics in operation at the end of the period    
373
      
331
  
                 
Clinic licenses sold but not yet developed    
107
      
146
  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
    Three Months Ended
    March 31,
    2017   2016
         
Net loss   $
(1,647,064
 )   $
(3,525,134
 )
                 
Weighted average common shares outstanding - basic    
13,042,595
      
12,567,901
  
Effect of dilutive securities:                
Stock options    
-
      
-
  
Weighted average common shares outstanding - diluted    
13,042,595
      
12,567,901
  
                 
Basic and diluted loss per share   $
(0.13
 )   $
(0.28
 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
    Three Months Ended
    March 31,
    2017   2016
Unvested restricted stock    
80,070
      
292,466
  
Stock options    
916,915
      
768,625
  
Warrants    
90,000
      
90,000